BMO Capital Starts ARMO BioSciences, Inc. (ARMO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Tanker struck by projectile in Strait of Hormuz
Jefferies Starts ARMO BioSciences, Inc. (ARMO) at Buy
February 20, 2018 2:23 AM ESTJefferies initiates coverage on ARMO BioSciences, Inc. (NASDAQ: ARMO) with a Buy rating and a price target of $61.00.
For an analyst ratings summary and ratings history on ARMO BioSciences, Inc. click here. For more ratings news on ARMO BioSciences, Inc. click here.
Shares of ARMO BioSciences, Inc. closed at $53.65 Friday.
... MoreBaird Starts ARMO BioSciences, Inc. (ARMO) at Outperform
February 20, 2018 1:57 AM ESTBaird initiates coverage on ARMO BioSciences, Inc. (NASDAQ: ARMO) with a Outperform rating and a price target of $67.00.
Analyst Brian Skorney comments "We see ARMO's pegylated, recombinant IL-10, AM0010, as a unique asset in the IO space. It has shown singleagent response... More
